Skip to main content

What the FDA labels say about taking them together

Probenecid and valganciclovir

Valganciclovir's FDA label of December 8, 2025 names probenecid in its drug interactions section; the probenecid label PlainMeds reads does not name valganciclovir. The valganciclovir label: “VALCYTE dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.”

Check it at the source: the probenecid FDA label on DailyMed (effective January 5, 2021, Lannett Company, Inc.); the valganciclovir FDA label on DailyMed (effective December 8, 2025, H2-Pharma, LLC).

What does the probenecid label say about valganciclovir?

Probenecid's label (effective January 5, 2021) does not name valganciclovir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Probenecid), Lannett Company, Inc., effective January 5, 2021 (SPL set ab497fd8-00c3-4364-b003-b39d21fbdf38), via openFDA; the full label on DailyMed

What does the valganciclovir label say about probenecid?

Valganciclovir label, drug interactions

Name of the Concomitant Drug: Probenecid; Change in the Concentration of Ganciclovir or Concomitant Drug: ↑ Ganciclovir; Clinical Comment: VALCYTE dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.

Source: FDA drug label (Valcyte), NDA021304 (Cheplapharm), as published by H2-Pharma, LLC, effective December 8, 2025 (SPL set 4c517a39-2ded-4c5a-8d56-276853414b31), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

6Probenecid generic labelers
19Valganciclovir generic labelers
ProbenecidValganciclovir
Labeled forGoutn/a
Boxed warningNoYes
Pharmacy cost (NADAC)$0.636 per tablet 500 mg tablet$1.91 per tablet 450 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?